Morepen Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on May 12, 2025, recommended Final Dividend of Rs. 0.20 per equity share.
MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors, at its meeting on May 12, 2025, recommended a final dividend of Rs. 0.20 per equity share (face value Rs. 2) for FY25, subject to shareholder approval. The company reported consolidated FY25 total income of Rs. 1,82,993.95 lakhs (up ~7.4% YoY) and net profit of Rs. 11,802.04 lakhs (up ~22.7% YoY), with EPS of Rs. 2.20 vs Rs. 1.88. Standalone performance was weaker, with net profit declining ~8.4% YoY to Rs. 10,157.52 lakhs and EPS at Rs. 1.90 vs Rs. 2.17. The Board approved an addendum to the Business Transfer Agreement with subsidiary Morepen Medipath Limited, revising the appointed date for the medical devices hive-off from February 1, 2025 to April 1, 2025. A wholly owned subsidiary will be incorporated in Dubai, UAE, to expand B2B and B2C medical device business. Dr. Morepen Limited's shareholding was diluted from 100% to 80% via warrant conversion, and Quick Med Private Limited was acquired as a step-down subsidiary with 64% effective holding.
The final dividend of Rs. 0.20/share is modest (10% on face value) and needs shareholder approval at the upcoming AGM. The mixed financial picture — strong consolidated growth driven by subsidiaries but a decline in standalone profits — along with ongoing corporate restructuring (medical device hive-off, share dilution, new acquisitions) suggests strategic reshaping of the business that investors should monitor for execution and future margin impact.